8-K: Silexion Reports Strong Q3 2025, Advances Clinical Trials

Silexion Therapeutics announced strong third-quarter 2025 financial results, significantly strengthening its balance sheet and advancing its lead RNAi therapy, SIL204, towards Phase 2/3 clinical trials.

Summary

• Silexion Therapeutics reported financial results for the third quarter ended September 30, 2025, showing significant improvements in its financial position.
• The company successfully raised approximately $9.5 million in gross proceeds during Q3 2025 through a public offering and warrant exercises.
• Cash and cash equivalents increased to $9.2 million as of September 30, 2025, up from $3.5 million at June 30, 2025, and $1.2 million at December 31, 2024.
• Shareholders' equity rose to $7.0 million as of September 30, 2025, a substantial improvement from a capital deficiency of $4.0 million at year-end 2024.
• Net loss for Q3 2025 decreased by 72.3% to $3.3 million (or $2.88 per share) compared to $11.9 million (or $274.25 per share) in Q3 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 49.3% to $7.5 million (or $10.36 per share) compared to $14.8 million (or $754.85 per share) in the same period of 2024.
• Research and Development (R&D) expenses for Q3 2025 were $2.2 million, a 31.3% decrease from $3.2 million in Q3 2024, primarily due to the absence of non-cash share-based compensation, partially offset by increased subcontractor costs.
• General and Administrative (G&A) expenses for Q3 2025 were $1.1 million, a 77.1% decrease from $4.8 million in Q3 2024, mainly due to the absence of non-cash share-based compensation.
• Preclinical data for SIL204 demonstrated exceptional efficacy across multiple human cancer cell lines, including five KRAS-driven cancer types and eight different cancer-causing mutations, with the first evidence of effectiveness in gastric cancer.
• Operational readiness for Phase 2/3 clinical trials of SIL204 is on track, with toxicology studies progressing as planned.
• Regulatory submissions are expected to be filed with the Israel Ministry of Health in Q4 2025 and in Germany and the European Union in Q1 2026.
• Clinical trial initiation for SIL204 is anticipated in the first half of 2026.
• Silexion partnered with AMS Advanced Medical Services GmbH as its CRO to support the upcoming Phase 2/3 clinical trials.
• The company regained full compliance with Nasdaq's minimum bid price and shareholders' equity requirements on September 23, 2025, securing continued listing on the Nasdaq Capital Market.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant financial improvements (increased cash, positive shareholders' equity, reduced losses), strong preclinical data expanding the potential of their lead candidate, clear progress towards Phase 2/3 clinical trials with defined timelines, and successful regaining of Nasdaq compliance. These are all strong indicators of positive momentum for a clinical-stage biotech.

Positives

• Significant strengthening of the balance sheet with cash and cash equivalents increasing to $9.2 million as of September 30, 2025, from $1.2 million at year-end 2024.
• Shareholders' equity improved substantially to $7.0 million from a capital deficiency of $4.0 million at year-end 2024.
• Net loss decreased by 72.3% in Q3 2025 and 49.3% for the nine months ended September 30, 2025, primarily due to the absence of one-time costs from the August 2024 Business Combination.
• Strong preclinical data for SIL204 showing exceptional efficacy across five KRAS-driven cancer types and eight mutations, including new evidence in gastric cancer.
• Clinical trial preparation for Phase 2/3 of SIL204 is on track, with regulatory submissions expected in Q4 2025 (Israel) and Q1 2026 (EU), and trial initiation in H1 2026.
• Successful partnership with AMS Advanced Medical Services GmbH, a CRO with 28 years of oncology clinical development experience, to support Phase 2/3 trials.
• Regained full compliance with Nasdaq listing requirements, ensuring continued trading on the Nasdaq Capital Market.

Risks

• Ability to successfully complete preclinical studies and initiate clinical trials.
• Impact of the regulatory environment and compliance complexities.
• Ability to obtain additional capital for future requirements.
• Ability to maintain Nasdaq listing.
• Actual results or events may differ materially from forward-looking projections due to various uncertainties and assumptions.

Future Outlook

Silexion Therapeutics anticipates filing regulatory submissions for its Phase 2/3 clinical trials of SIL204 with the Israel Ministry of Health in Q4 2025 and in Germany and the European Union in Q1 2026. The company expects to initiate these clinical trials in the first half of 2026, continuing its focus on advancing its lead product candidate for locally advanced pancreatic cancer and other KRAS-driven cancers. Future capital-raising and operational readiness activities are also part of the ongoing strategy.

Management Comments

• Ilan Hadar, Chairman and CEO: "The third quarter marked a period of strong scientific progress and continued operational momentum for Silexion. With new preclinical data demonstrating SIL204s exceptional efficacy across a broad range of KRAS mutations and multiple cancer types, we are entering the next phase of development with great confidence."
• Ilan Hadar, Chairman and CEO: "The selection of a CRO partner and the successful completion of additional financing further strengthen our readiness to initiate Phase 2/3 clinical trials in the first half of 2026. Our focus now is on completing regulatory submissions in Israel and the EU and advancing toward the clinic with the same precision and discipline that have defined our progress to date."
• Mirit Horenshtein Hadar, CFO: "Our financial results for the third quarter reflect meaningful improvement in both our balance sheet and operating efficiency. The successful $9.5 million of financings completed during the quarter significantly increased our cash position and shareholders equity, contributing to maintaining our Nasdaq listing."
• Mirit Horenshtein Hadar, CFO: "We believe our strengthened capital structure and financial discipline provide a solid foundation to support us as we advance towards our upcoming regulatory and clinical milestones."

Industry Context

Silexion Therapeutics operates in the highly competitive clinical-stage biotechnology sector, specifically focusing on RNA interference (RNAi) therapies for KRAS-driven cancers. KRAS mutations are considered the most common oncogenic gene driver in human cancers, making this a significant and challenging area of oncology research with high unmet medical need. The successful preclinical data across multiple KRAS-driven cancer types positions SIL204 as a potential platform technology, which could be a significant differentiator in the market if clinical trials prove successful. The advancement to Phase 2/3 trials and securing funding are critical steps in a capital-intensive industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. However, the focus on KRAS-driven cancers is a highly active area in oncology, with several large pharmaceutical and biotech companies (e.g., Amgen with Lumakras, Mirati Therapeutics with Krazati) having approved or advanced therapies targeting specific KRAS mutations. Silexion's approach with SIL204 as a potential pan-KRAS RNAi therapeutic could offer a broader treatment scope if successful, differentiating it from mutation-specific inhibitors.

Corporate Governance

Related Party Transactions

• Research and Development expenses included $0 from related party for the nine months ended September 30, 2025, compared to $1,796 thousand for the same period in 2024.
• Research and Development expenses included $0 from related party for the three months ended September 30, 2025, compared to $1,762 thousand for the same period in 2024.
• General and Administrative expenses included $96 thousand from related party for the nine months ended September 30, 2025, compared to $2,972 thousand for the same period in 2024.
• General and Administrative expenses included $38 thousand from related party for the three months ended September 30, 2025, compared to $2,948 thousand for the same period in 2024.
• Financial expenses (income), net included $203 thousand from related party for the nine months ended September 30, 2025, compared to $(47) thousand for the same period in 2024.
• Financial expenses (income), net included $(26) thousand from related party for the three months ended September 30, 2025, compared to $(182) thousand for the same period in 2024.
• Related Party Promissory Note balance was $1,540 thousand as of September 30, 2025, down from $2,961 thousand as of December 31, 2024, due to a partial conversion.

Stakeholder Impact

• Shareholders: Positively impacted by the strengthened balance sheet, reduced net loss, successful capital raise, and regaining of Nasdaq compliance, which enhances liquidity and investor confidence.
• Patients: Potential for new therapeutic options for KRAS-driven cancers, as SIL204 advances towards clinical trials with promising preclinical data.
• Employees: Continued operational momentum and progress towards clinical milestones provide stability and clear objectives.
• Creditors: Improved financial health and increased cash position enhance the company's ability to meet its obligations.

Next Steps

• Complete toxicology studies for SIL204.
• File regulatory submissions with the Israel Ministry of Health in Q4 2025.
• File regulatory submissions in Germany and the European Union in Q1 2026.
• Initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026.
• Continue advancing the lead product candidate for locally advanced pancreatic cancer and other KRAS-driven cancers.

Key Dates

Recommendation

Silexion Therapeutics has demonstrated significant positive momentum with a substantially strengthened balance sheet, reduced net losses, promising preclinical data for its lead candidate SIL204, and a clear path towards Phase 2/3 clinical trials. Regaining Nasdaq compliance also removes a key uncertainty. However, as a clinical-stage biotechnology company, it remains pre-revenue and subject to the inherent high risks of drug development, including clinical trial success, regulatory approvals, and future funding needs. While the recent developments are encouraging, a 'Hold' recommendation is appropriate for a seasoned investor, acknowledging the positive progress while maintaining caution due to the early stage of its primary asset and the long, uncertain path to commercialization.

Keywords

Silexion Therapeutics, SLXN, RNA interference, RNAi, KRAS-driven cancers, SIL204, Phase 2/3 clinical trials, Oncology, Biotechnology, Financial results, Q3 2025, Balance sheet, Capital raise, Nasdaq compliance, Preclinical data, Pancreatic cancer, Lung cancer, Colorectal cancer, Gastric cancer